Skip to main content

Advertisement

SpringerLink
Log in

Antiangiogenic therapy in myelodysplastic syndromes: Is there a role?

  • Published:
Current Hematologic Malignancy Reports Aims and scope Submit manuscript

Abstract

Angiogenesis has been shown to play a pivotal role in the growth and metastasis of solid tumors. Numerous in vitro and translational research studies have implicated a role for angiogenesis in the pathogenesis of myelodysplastic syndrome (MDS). Although the role of angiogenesis inhibitors in the treatment of solid tumors has evolved significantly over the past 5 years, their role in the treatment of hematologic malignancies such as MDS remains investigational. MDS treatment historically has been challenging, but the US Food and Drug Administration in the past 4 years has approved the hypomethylating agents 5-azacitidine and decitabine and the immunomodulatory agent lenalidomide for the 5q-syndrome. These approvals highlight recent successes in identifying and targeting pathobiologic abnormalities that contribute to MDS. Drugs such as lenalidomide and the first-generation analogue from which it was derived, thalidomide, exert multiple mechanisms of action but partially act via inhibition of angiogenesis. Over the next 5 to 10 years, preclinical and clinical evaluation of agents with more strictly defined antiangiogenic activity, such as inhibitors of vascular endothelial growth factor, or agents with partial antiangiogenesis activity, such as multitargeted tyrosine kinase inhibitors, will ultimately help define the utility of angiogenic blockade in MDS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Carmeliet P: Angiogenesis in life, disease and medicine. Nature 2005, 438:932–936.

    Article  PubMed  CAS  Google Scholar 

  2. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182–1186.

    Article  PubMed  CAS  Google Scholar 

  3. Hurwitz H, Fehrenbacher L, Novotny W, et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335–2342.

    Article  PubMed  CAS  Google Scholar 

  4. Midgley R, Kerr D: Bevacizumab—current status and future directions. Ann Oncol 2005, 16:999–1004.

    Article  PubMed  Google Scholar 

  5. Escudier B, Eisen T, Stadler WM, et al.: Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125–134.

    Article  PubMed  CAS  Google Scholar 

  6. Faivre S, Djelloul S, Raymond E: New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors. Semin Oncol 2006, 33:407–420.

    Article  PubMed  CAS  Google Scholar 

  7. Rock EP, Goodman V, Jiang JX, et al.: Food and Drug Administration drug approval summary: sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist 2007, 12:107–113.

    Article  PubMed  CAS  Google Scholar 

  8. Brunner G, Nguyen H, Gabrilove J, et al.: Basic fibroblast growth factor expression in human bone marrow and peripheral blood cells. Blood 1993, 81:631–638.

    PubMed  CAS  Google Scholar 

  9. Leung DW, Cachianes G, Kuang WJ, et al.: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246:1306–1309.

    Article  PubMed  CAS  Google Scholar 

  10. Podar K, Anderson KC: The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications. Blood 2005, 105:1383–1395.

    Article  PubMed  CAS  Google Scholar 

  11. List AF: Vascular endothelial growth factor signaling pathway as an emerging target in hematologic malignancies. Oncologist 2001, 6(Suppl 5):24–31.

    Article  PubMed  CAS  Google Scholar 

  12. Ziegler BL, Valtieri M, Porada GA, et al.: KDR receptor: a key marker defining hematopoietic stem cells. Science 1999, 285:1553–1558.

    Article  PubMed  CAS  Google Scholar 

  13. Aguayo A, Estey E, Kantarjian H, et al.: Cellular vascular endothelial growth factor is a predictor of outcome in patients with acute myeloid leukemia. Blood 1999, 94:3717–3721.

    PubMed  CAS  Google Scholar 

  14. Giles FJ: The vascular endothelial growth factor (VEGF) signaling pathway: a therapeutic target in patients with hematologic malignancies. Oncologist 2001, 6(Suppl 5):32–39.

    Article  PubMed  CAS  Google Scholar 

  15. Hussong JW, Rodgers GM, Shami PJ: Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000, 95:309–313.

    PubMed  CAS  Google Scholar 

  16. Aguayo A, Kantarjian H, Manshouri T, et al.: Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000, 96:2240–2245.

    PubMed  CAS  Google Scholar 

  17. Lundberg LG, Lerner R, Sundelin P, et al.: Bone marrow in polycythemia vera, chronic myelocytic leukemia, and myelofibrosis has an increased vascularity. Am J Pathol 2000, 157:15–19.

    PubMed  CAS  Google Scholar 

  18. Vacca A, Ribatti D: Bone marrow angiogenesis in multiple myeloma. Leukemia 2006, 20:193–199.

    Article  PubMed  CAS  Google Scholar 

  19. Rajkumar SV, Leong T, Roche PC, et al.: Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000, 6:3111–3116.

    PubMed  CAS  Google Scholar 

  20. Kumar S, Gertz MA, Dispenzieri A, et al.: Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy. Bone Marrow Transplant 2004, 34:235–239.

    Article  PubMed  CAS  Google Scholar 

  21. Pruneri G, Bertolini F, Soligo D, et al.: Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999, 81:1398–1401.

    Article  PubMed  CAS  Google Scholar 

  22. Alexandrakis MG, Passam FH, Pappa CA, et al.: Serum evaluation of angiogenic cytokine basic fibroblast growth factor, hepatocyte growth factor and TNF-alpha in patients with myelodysplastic syndromes: correlation with bone marrow microvascular density. Int J Immunopathol Pharmacol 2005, 18:287–295.

    PubMed  CAS  Google Scholar 

  23. Wimazal F, Krauth MT, Vales A, et al.: Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category. Leuk Lymphoma 2006, 47:451–460.

    Article  PubMed  CAS  Google Scholar 

  24. Alexandrakis MG, Passam FH, Kyriakou DS, et al.: Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes. J Mol Histol 2004, 35:857–863.

    Article  PubMed  CAS  Google Scholar 

  25. Lundberg LG, Hellstrom-Lindberg E, Kanter-Lewensohn L, et al.: Angiogenesis in relation to clinical stage, apoptosis and prognostic score in myelodysplastic syndromes. Leuk Res 2006, 30:247–253.

    Article  PubMed  Google Scholar 

  26. Keith T, Araki Y, Ohyagi M, et al.: Regulation of angiogenesis in the bone marrow of myelodysplastic syndromes transforming to overt leukaemia. Br J Haematol 2007, 137:206–215.

    Article  PubMed  CAS  Google Scholar 

  27. Aguayo A, Kantarjian HM, Estey EH, et al.: Plasma vascular endothelial growth factor levels have prognostic significance in patients with acute myeloid leukemia but not in patients with myelodysplastic syndromes. Cancer 2002, 95:1923–1930.

    Article  PubMed  Google Scholar 

  28. Bellamy WT, Richter L, Sirjani D, et al.: Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001, 97:1427–1434.

    Article  PubMed  CAS  Google Scholar 

  29. Alexandrakis MG, Passam FH, Pappa CA, et al.: Relation between bone marrow angiogenesis and serum levels of angiogenin in patients with myelodysplastic syndromes. Leuk Res 2005, 29:41–46.

    Article  PubMed  CAS  Google Scholar 

  30. Brunner B, Gunsilius E, Schumacher P, et al.: Blood levels of angiogenin and vascular endothelial growth factor are elevated in myelodysplastic syndromes and in acute myeloid leukemia. J Hematother Stem Cell Res 2002, 11:119–125.

    Article  PubMed  CAS  Google Scholar 

  31. Lai R, Estey E, Shen Y, et al.: Clinical significance of plasma endostatin in acute myeloid leukemia/myelodysplastic syndrome. Cancer 2002, 94:14–17.

    Article  PubMed  CAS  Google Scholar 

  32. Hu Q, Dey AL, Yang Y, et al.: Soluble vascular endothelial growth factor receptor 1, and not receptor 2, is an independent prognostic factor in acute myeloid leukemia and myelodysplastic syndromes. Cancer 2004, 100:1884–1891.

    Article  PubMed  CAS  Google Scholar 

  33. Alvi S, Borok RZ, Shaher A, et al.: Thalidomide significantly modifies bone marrow microenvironment in myelodysplastic syndrome (MDS) patients [abstract]. Blood 2002, 100:375a. Abstract 1454.

    Article  CAS  Google Scholar 

  34. Shetty V, Alvi S, Zorat F, et al.: Effect of the antiangiogenic thalidomide on the biological characteristics of patients with myelodysplastic syndromes [abstract]. Blood 2002, 100:337b. Abstract 4902.

    Google Scholar 

  35. Raza A, Meyer P, Dutt D, et al.: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001, 98:958–965.

    Article  PubMed  CAS  Google Scholar 

  36. Moreno-Aspitia A, Colon-Otero G, Hoering A, et al.: Thalidomide therapy in adult patients with myelodysplastic syndrome. A North Central Cancer Treatment Group phase II trial. Cancer 2006, 107:767–772.

    Article  PubMed  CAS  Google Scholar 

  37. Strupp C, Germing U, Aivado M, et al.: Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002, 16:1–6.

    Article  PubMed  CAS  Google Scholar 

  38. Bouscary D, Legros L, Tulliez M, et al.: A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies. Br J Haematol 2005, 131:609–618.

    Article  PubMed  CAS  Google Scholar 

  39. Richardson PG, Schlossman RL, Weller E, et al.: Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100:3063–3067.

    Article  PubMed  CAS  Google Scholar 

  40. Davies FE, Raje N, Hideshima T, et al.: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98:210–216.

    Article  PubMed  CAS  Google Scholar 

  41. Gupta D, Treon SP, Shima Y, et al.: Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications. Leukemia 2001, 15:1950–1961.

    PubMed  CAS  Google Scholar 

  42. Mahadevan D, List AF, Tate W, et al.: The immunomodulatory thalidomide analog CC5013 is a potent receptor tyrosine kinase (RTK) inhibitor that abolishes vascular endothelial growth factor (VEGF) trophic response in malignant myeloid progenitors. Leuk Res 2003, 27:S108–S109.

    Google Scholar 

  43. List A, Kurtin S, Roe DJ, et al.: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352:549–557

    Article  PubMed  CAS  Google Scholar 

  44. List A, Dewald G, Bennett J, et al.: Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456–1465.

    Article  PubMed  CAS  Google Scholar 

  45. Raza A, Reeves JA, Feldman EJ, et al.: Phase II study of lenalidomide in transfusion-dependent, low-and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2007, In press.

  46. Buesche G, Dieck S, Giagounidis A, et al.: Anti-angiogenic in vivo effect of lenalidomide (CC-5013) in myelodysplastic syndrome with del(5q) chromosome abnormality and its relation to the course of disease [abstract]. Blood 2005, 106:113a.

    Google Scholar 

  47. List A, Beran M, DiPersio J, et al.: Opportunities for Trisenox (arsenic trioxide) in the treatment of myelodysplastic syndromes. Leukemia 2003, 17:1499–1507.

    Article  PubMed  CAS  Google Scholar 

  48. Miller WH Jr, Schipper HM, Lee JS, et al.: Mechanisms of action of arsenic trioxide. Cancer Res 2002, 62:3893–3903.

    PubMed  CAS  Google Scholar 

  49. Lew YS, Brown SL, Griffin RJ, et al.: Arsenic trioxide causes selective necrosis in solid murine tumors by vascular shutdown. Cancer Res 1999, 59:6033–6037.

    PubMed  CAS  Google Scholar 

  50. Roboz GJ, Dias S, Lam G, et al.: Arsenic trioxide induces dose-and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition of angiogenesis. Blood 2000, 96:1525–1530.

    PubMed  CAS  Google Scholar 

  51. Schiller GJ, Slack J, Hainsworth JD, et al.: Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes. J Clin Oncol 2006, 24:2456–2464.

    Article  PubMed  CAS  Google Scholar 

  52. Vey N, Bosly A, Guerci A, et al.: Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol 2006, 24:2465–2471.

    Article  PubMed  CAS  Google Scholar 

  53. Giles FJ, Stopeck AT, Silverman LR, et al.: SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003, 102:795–801.

    Article  PubMed  CAS  Google Scholar 

  54. Giles FJ, Bellamy WT, Estrov Z, et al.: The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Leuk Res 2006, 30:801–811.

    Article  PubMed  CAS  Google Scholar 

  55. Gupta P, Sanford BL, Yu D, et al.: A phase II study of an oral VEGF receptor tyrosine kinase inhibitor (PTK787/ZK222584) in patients with myelodysplastic syndrome (MDS): Cancer and Leukemia Group B Study 10105 [abstract]. Blood 2006, 108:753a.

    Google Scholar 

  56. Parker J, Mufti GJ: Ras and myelodysplasia: lessons from the last decade. Semin Hematol 1996, 33:206–224.

    PubMed  CAS  Google Scholar 

  57. Casey PJ, Solski PA, Der CJ, et al.: p21ras is modified by a farnesyl isoprenoid. Proc Natl Acad Sci U S A 1989, 86:8323–8327.

    Article  PubMed  CAS  Google Scholar 

  58. Fenaux P, Raza A, Mufti GJ, et al.: A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate-to high-risk myelodysplastic syndrome. Blood 2007, 109:4158–4163.

    Article  PubMed  CAS  Google Scholar 

  59. Delmas C, End D, Rochaix P, et al.: The farnesyltransferase inhibitor R115777 reduces hypoxia and matrix metalloproteinase 2 expression in human glioma xenograft. Clin Cancer Res 2003, 9:6062–6068.

    PubMed  CAS  Google Scholar 

  60. Izbicka E, Campos D, Carrizales G, et al.: Biomarkers of anticancer activity of R115777 (Tipifarnib, Zarnestra) in human breast cancer models in vitro. Anticancer Res 2005, 25:3215–3223.

    PubMed  CAS  Google Scholar 

  61. Gu WZ, Tahir SK, Wang YC, et al.: Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo. Eur J Cancer 1999, 35:1394–1401.

    Article  PubMed  CAS  Google Scholar 

  62. Desrosiers RR, Cusson MH, Turcotte S, et al.: Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration. Int J Cancer 2005, 114:702–712.

    Article  PubMed  CAS  Google Scholar 

  63. Takada Y, Khuri FR, Aggarwal BB: Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis. J Biol Chem 2004, 279:26287–26299.

    Article  PubMed  CAS  Google Scholar 

  64. Han JY, Oh SH, Morgillo F, et al.: Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer. J Natl Cancer Inst 2005, 97:1272–1286.

    Article  PubMed  CAS  Google Scholar 

  65. Cortes J, Albitar M, Thomas D, et al.: Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies. Blood 2003, 101:1692–1697.

    Article  PubMed  CAS  Google Scholar 

  66. Mesa RA, Camoriano JK, Geyer SM, et al.: A phase II trial of tipifarnib in myelofibrosis: primary, post-polycythemia vera and post-essential thrombocythemia. Leukemia 2007, 21:1964–1970.

    Article  PubMed  CAS  Google Scholar 

  67. Gotlib J, Jamieson CHM, List A, et al.: Phase II study of bevacizumab (anti-vegf humanized monoclonal antibody) in patients with myelodysplastic syndrome (MDS): preliminary results [abstract]. Blood 2003, 102:425a. Abstract 1545.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology, Stanford Cancer Center, Room 2324, 875 Blake Wilbur Drive, Stanford, CA, 94305, USA

    Jason Gotlib

Authors
  1. Stephen T. Oh
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jason Gotlib
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jason Gotlib.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Oh, S.T., Gotlib, J. Antiangiogenic therapy in myelodysplastic syndromes: Is there a role?. Curr Hematol Malig Rep 3, 10–18 (2008). https://doi.org/10.1007/s11899-008-0003-0

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11899-008-0003-0

Keywords

Search

Navigation